small molecule

NEVANAC

NEPAFENAC

Loss of exclusivityJanuary 2027latest FDA-listed patent expiry
CompanyHARROW EYE LLC

Drug detail

Brand nameNEVANAC
Active ingredientNEPAFENAC
Strength0.1%
Dosage formSUSPENSION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalAugust 2005
Marketing statusRX

Listed patents

PatentExpiresType
7834059January 2027use U-1095

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found